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Summary: Serum cholinesterase catalytic concentrations were estimated in 26 patients diagnosed as having sys-
temic sepsis syndrome (septic shock) in the Intensive Care Unit (12 were admitted with the diagnosis of systemic
sepsis syndrome while 14 patients developed the syndrome while in the unit) and in 66 normal, healthy subjects.
The assay was performed for 7 consecutive days in the patient group. There was a very significant decrease in the
level of cholinesterase in the patient group from the onset of the study as compared to the control group
(P < 0.00001). This decrease remained during the course of the seven day study period, indicating hepatic dysfunc-
tion early in the diagnosis. When compared to other conventional liver function tests, serum cholinesterase seems
to change earlier on in the diagnosis. Prothrombin time showed a pattern of change similar to that of serum
cholinesterase. There was a significant relationship between the catalytic concentration of serum cholinesterase and
the outcome of the systemic sepsis syndrome, the level being significantly lower in patients who died in comparison
to those who lived. It seems that serum cholinesterase is a sensitive indicator of hepatic dysfunction in the systemic
sepsis syndrome.
Introduction linesterase in serum has been previously used as an in-
dex of nutritional status and biosynthetic function of the
Septic shock is being diagnosed increasingly frequently liyer (1)> and as a marker Qf life.threatening COcaine in-
partly due to a greater awareness of this condition and toxication (2). ϊη addition, it has also been used as a
partly due to an actual increase in its incidence in recent sensitive index of serious organophosphorous poison-
years. In spite of rapid advances in laboratory techniques jng (3)
and clinical pharmacology, the initial diagnosis remains _ . , , . ,.ν · " , " Γ „°J . ° xhls study was undertaken to evaluate the diagnostica clinical one and antibiotic therapy is essentially em- ,, 1 r . . . 4 . . ~ u ι - *. . , , , , . . ,. . . . . . usefulness of serial determination of serum cholmester-pmc. To the practising, clinician, systemic sepsis is a ase m g ̂  ̂  ̂ .̂  djagnosis Q g gyn_
diagnostic challenge and therapeutic dilemma. Hepatic ^^ admitted tQ thg Intensive Care Unit (ICU) ̂
dysfunction represents a major and often life-threatening objective was to study the value of this marker as an
feature of this sepsis syndrome. Despite the availability indicator of hepatic dysfunction in systemic sepsis. In
of various enzymological assays for liver disease, no addition, we attempted to correlate the catalytic concen-
satisfactory marker of early hepatic dysfunction in the tration of serum cholinesterase and the outcome of treat-
sepsis syndrome exists. ment in patients with sepsis.
Serum cholinesterase (EC 3.1.1.8) is an important lipo-
protein enzyme synthesized by the liver. This enzyme is Patients and Methods
capable of hydrolysis of succinylcholine and ester-linked Adult patjents admitted to the multidisciplinary Intensive care Unit
local anaesthetics such as procaine. Estimation of cho- at the Asir Central Hospital in Abha, Saudi Arabia were included
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in this study. Patients admitted with a diagnosis of systemic sepsis
(12 patients) were enrolled in the study after obtaining die appro-
priate informed consent. In addition, patients who developed the
sepsis syndrome while in the Intensive Care Unit (14 patients) were
also included in the study. The study was approved by our local
hospital ethical committee. The severity of the clinical condition
was assessed by the APACHE Π scoring system (4) upon admis-
sion or upon diagnosis of sepsis syndrome. All patients in this
study were Saudi Arabian nationals. The mean age of patients was
54.6 years (range 21-99 years). There was a total of 26 patients
in the study group (9 males and 17 females).
Patient who had known pre-existing hypoproteinaemia or hypoal-
buminaemia, undernutrition, pregnancy, and myxoedema were alJ
excluded from the study. Similarly, patients receiving anti-neoplas-
tic drugs phenothiazines, cimetidine, or procainamide were also
excluded from the study. All these conditions are known to increase
the serum catalytic concentration of cholinesterase (5). In addition,
patients receiving blood transfusion (but not blood substituents)
were excluded from the study. All patients with any clinical or
biochemical evidence of pre-existing liver disease were excluded
from the study.
The sepsis syndrome (6) in this study was defined according to
the criteria of Hammerschmidt et al. (7). The clinical entity was
considered to be present when two or more of the criteria from
group (A) and any one criterion from group (B) were observed in
a patient belonging to a high risk category.
In brief, Group A criteria were defined as:
1. Rectal temperature above 39 °C or below 36 °C
2. Leukocyte count above 12 X 109/1 or less than 3 X 109/1.
3. Differential count showing > 10% immature granulocytes.
4. Blood culture positive for pathogens.
5. Known or suspected local source of infection with a positive
culture for a pathogen.
Group B criteria were defined as:
1. Persistent metabolic acidosis with a standard base excess
< 5 mmol/1.
2. Systemic vascular resistance < 800 dynes/S in patients with a
pulmonary artery catheter.
3. Otherwise unexplained hypotension with systolic blood pressure
< 90 mm Hg for over 2 hours.
The presence of any unexplained deterioration of haemodynamic,
respiratory, neurologic, renal, or coagulation quantities was consid-
ered strongly corroborative.
Blood samples were obtained by sterile technique using a fresh
venipuncture site each time. The blood was split into two tubes,
one plain tube for serum collection, and the other a lithium heparin
tube for plasma collection. The plasma sample was assayed for
general chemistry using an automated analyzer (Hitachi 704 sys-
tem, Boehringer Mannheim, Germany). The serum was stored at
-20 °C for subsequent cholinesterase assay. This latter assay was
performed in batches and the samples were stored for a maximum
of 8 weeks. Serum cholinesterase was assayed using a Hitachi 704
analyzer utilizing the method ofDietz et al. (8) as modified by den
Blaauwen et al. (9). The assay was performed at 30 °C. Samples
showing values greater than 12000 U/l were diluted with 2 vol-
umes of normal saline prior to assay (as suggested by the manufac-
turer). Controls were included (both high and low). The intra-assay
variation was 3% while the inter-assay variation was 7%.
The following constituents were assayed on the collected blood
samples once the clinical diagnosis was made: complete blood
count, sodium, potassium, urea, creatinine, liver function tests in-
cluding alaninc aminotransferase, aspartate aminotransferase, alka-
line phosphatase, total protein, albumin, prothrombin and activated
partial thromboplastin times. In addition, serum cholinesterase was
also estimated as described above. Blood samples were drawn daily
thereafter for the estimation of the above quantities (whenever pos-
sible) up to the first seven days or until the time of the patient's
discharge or death, whichever was earlier. A positive blood culture
was not considered necessary for inclusion in this study. However,
blood was collected aseptically for aerobic and anaerobic culture
on day 1 and as appropriate thereafter as a part of the routine
Intensive Care Unit protocol.
Blood was also collected from 66 apparently healthy age and sex
matched normal controls to establish the baseline values for serum
cholinesterase in the local population. None* of the control patients
had known hepatic disease, undernutrition, obesity, myxoedema
or pregnancy.
Statistical analysis was performed using the SPSS/PC statistical
package loaded onto a personal computer. Since most of the quanti-
ties had non-parametric distribution, the Mann-Whitney U test was
used for statistical evaluation. When the specific quantity had a
normal distribution, the Student t-test was used.
Results
Table 1 summarizes the results of the comparison of the
catalytic concentration of serial serum cholinesterase ob-
tained from the patient group at the entry of the study
on day 1 as compared to the control group. Twelve pa-
tients in the study were admitted with the diagnosis of
sepsis syndrome and 14 patients developed the sepsis
while in the Intensive Care Unit. In the first group, the
mean APACHE II score was 26.3 ± 3.46 while in iffe
second group the mean APACHE II score upon diagno-
sis was 29 ± 4.90. There was a very significant differ-
ence (P < 0.00001) between the patient group and the
control group with serum cholinesterase catalytic con-
centrations being greatly depressed in the patient group
in relation to the control group. This depression was
noted throughout the remaining six days of sampling. It
should be noted that approximately 20% of patients in
each of the seven study days showed a cholinesterase
catalytic concentration within the "normal range". It was
Tab. I Comparison between the catalytic concentration of serum
cholinesterase in each day of the study and the control value. Val-

































































* P value was obtained by comparison between each day value
and the controls using the Mann-Whitney U test.
The normal range for eholinesterase level was arbitrarily chosen to
be 7216 ± 1000 U/l.
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interesting to observe that the same patients also showed
similar trends in each of the seven days.
Table 2 shows the cumulative data of plasma alanine
aminotransferase, alkaline phosphatase, prothrombin
time and serum cholinesterase for the patient group in
each day of the study (total 7 days). It can be seen from
this table that the values of alanine aminotransferase
were very modestly elevated at the beginning of the
study and tended to come down towards normal baseline
values by the 4th day. On the other hand, serum cholin-
esterase catalytic concentrations were significantly de-
pressed at the beginning of the study and continued to
be low throughout the seven day follow-up period.
Prothrombin time showed a similar trend to that of cho-
linesterase since it was prolonged at the beginning and
remained so for the seven days of the study. Alkaline
phosphatase did not show any significant change from
baseline values throughout the study period.
Table 3 summarizes the results of analysis of serum cho-
linesterase catalytic concentrations according to the out-
comes (fatal or non-fatal) of the sepsis. A significant
difference was observed between the catalytic concen-
trations of cholinesterase in both groups, the level being
lower in those who had fatal outcome compared to those
who survived the systemic sepsis syndrome.
Tab. 3 Comparison of cholinesterase values in sera from patients












P value was obtained by Mann-Whitney U test.
Discussion
Systemic sepsis syndrome (previously termed septic
shock syndrome) is a frequently encountered problem in
Intensive Care Unit practice and its incidence may be
increasing. While there is little doubt that the main
pathogenesis is related to the liberation of endotoxins
from Gra/w-negative bacteria, other mechanisms may
also be operational (10). It has been shown previously
that early application of aggressive therapy (both sup-
portive and definitive) leads to a reduction in mortality
(6). One major aspect of the systemic sepsis syndrome
is the hepatic dysfunction which accompanies it. The
objective of this study was to examine the use of the
serum cholinesterase level as an indicator of hepatic
dysfunction in sepsis syndrome.
Our results have shown that there is a decrease in the
catalytic concentration of serum cholinesterase in pa-
tients with this syndrome. This decrease was maintained
throughout the 7 day study period. This is an important
observation, since serum cholinesterase seems to show
the depression rather early (day 1) and continues there-
after, suggesting that it may be a useful corroborative
marker supporting the clinical diagnosis. It is interesting
to note that the serum cholinesterase has a long half-life
in circulation (5). This may suggest that any change in
its level should be rather slow after the onset of the
sepsis syndrome. However, it is clear from our results
that this is not the case, a fact which may be explained
by the sensitivity of the biosynthetic mechanism of this
enzyme to the effect of systemic sepsis. Other conven-
tional liver function tests such as alanine aminotransfer-
ase did not show any reliable pattern of elevation.
Prothrombin time, once considered to be a sensitive in-
dex of acute liver disease was clearly prolonged yielding
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information similar to that of cholinesterase. This is ex-
pected, since most of the coagulation factors are pro-
duced by the liver and have short half-lives (about
S-14h), thus showing prolongation in acute liver dis-
ease. Plasma alkaline phosphatase, on the other hand,
did not show any significant change, an expected obser-
vation since biliary obstruction is not a major feature of
the systemic sepsis syndrome.
Often, patients with evolving sepsis syndrome may have
to undergo emergency surgery of an exploratory or de-
finitive nature. In such cases, suxamethonium (a short-
acting depolarising muscle relaxant) is the drug of
choice for endotracheal intubation. This drug is depen-
dent on plasma cholinesterase for the timely termination
of its action. Fortunately however, the lower catalytic
concentration of cholinesterase in these patients is of no
clinical significant since as little as 30% of normal en-
zyme activity is adequate to prevent unacceptably long
duration of action (5). The most common cause of the
so-called "suxamethonium apnoea" is not the low cata-
lytic concentrations of the enzyme, but the presence of
an atypical enzyme which results from an autosomal re-
cessive gene.
Another aspect of interest was to observe any correlation
between the mortality of patients with sepsis syndrome
and the catalytic concentration of serum cholinesterase.
It is reasonable to assume that patients with more severe
sepsis (which was likely to be fatal) should have lower
catalytic concentrations of serum· 'cholinesterase than
those without mortality. Our results confirmed this.
Hence serum cholinesterase seemed to be a reliable
prognostic marker in systemic sepsis. If this observation
is confirmed in subsequent studies, it carries a clinical
implication by helping to predict poor outcome from the
outset of the sepsis syndrome in those with low catalytic
concentrations and hence such patients will be treated
very aggressively from the onset.
This study, by virtue of the limited number of patients
involved, is only a preliminary one and further studies
involving larger number of patients are needed to sub-
stantiate our observations.
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